Skip to main content
Glama

Openiban

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate read-only, idempotent, open-world behavior, and the description adds substantial value: cascading internal lookups, graceful degradation when external sources fail, returning figi_candidates on ambiguity, explicit unresolved identifiers, and source-labeling of results. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but densely packed with necessary behavioral details, examples, and constraints. It is front-loaded with trigger phrases and organized by supported types, and while not maximally concise, every sentence contributes useful guidance.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Even without an output schema, the description thoroughly explains what results look like (identifiers with source labels, unresolved section, figi_candidates), failure modes, internal cascading, and coverage limits. An agent has enough context to call the tool correctly and interpret its response.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema coverage is 100%, the description significantly enhances parameter understanding by explaining that value must be the entity name only, that bond issuer names must be exact, and that trailing security-class words will cause lookup failure. This goes well beyond the schema's basic property descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states that this tool resolves user-spoken names into canonical/official identifiers required by other tools, with explicit supported types (company, drug). It names concrete query patterns and distinguishes itself from the sibling tools by focusing on name-to-ID resolution.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit usage guidance: 'Use FIRST whenever you have a name but need an ID,' plus detailed examples of when each type applies. It does not explicitly name sibling alternatives or describe when NOT to use this tool, but the context provided is strong enough for an agent to select it appropriately.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Openiban toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Multiple tools have heavily overlapping purposes: ask_pipeworx and ask_pipeworx_beta are explicitly identical right now, and the polymarket_* family (edges, arbitrage, edge_tracker, fill_risk) blurs together for an agent trying to pick one. entity_profile and recent_changes also both pull company data, and ai_visibility_check vs scan_competitor_ai_presence are single-vs-multi variants of the same probe.

Naming Consistency3/5

Naming is mostly snake_case and readable, with many verb_noun forms (validate_iban, generate_llms_txt, resolve_entity). However, there are bare verbs (remember, forget, recall, subscribe, unsubscribe), noun phrases (entity_profile, recent_changes, pipeworx_trending), and inconsistent prefixes (ask_ vs polymarket_ vs suggest_) that break a clear pattern.

Tool Count3/5

33 tools is borderline-heavy for a data-research API, but the bigger issue is that the server is named Openiban yet contains only two IBAN tools and 31 unrelated Pipeworx/data tools. The count feels bloated and misaligned with the server's apparent identity, though not extreme enough for a 1 or 2.

Completeness2/5

For the Pipeworx data-research domain the surface is quite rich (query, deep research, entity profiles, comparisons, subscriptions, memory). For the server's stated IBAN purpose, only validate and suggest_iban exist — no generation, parsing, batch checks, or bank detail coverage — so the tool set is severely incomplete relative to the server name.

Resources